Financial Performance - Domestic market revenue grew by 17.77% year-on-year in Q1 2023, while overseas market revenue increased by 31.19%[5] - The company achieved operating revenue of CNY 686,668,622.18, representing a year-on-year increase of 21.87%[50] - Net profit attributable to shareholders reached CNY 137,535,031.82, up 21.15% compared to the same period last year[50] - Net profit for Q1 2023 was ¥139,509,813.51, representing a 22.5% increase from ¥113,932,456.54 in Q1 2022[73] - Basic and diluted earnings per share were both ¥0.43, reflecting a year-on-year increase of 19.44%[11] - Basic and diluted earnings per share were both CNY 0.43, compared to CNY 0.36 in the same period last year[62] Cash Flow and Assets - Net cash flow from operating activities reached approximately ¥106.25 million, representing an increase of 8.78%[11] - Cash flow from operating activities generated a net amount of ¥106.25 million, up from ¥97.67 million in the previous period[40] - Cash flow from operating activities in Q1 2023 was ¥622,326,845.23, an increase from ¥570,087,834.27 in Q1 2022[74] - Cash and cash equivalents at the end of the period amounted to approximately ¥1.26 billion, down from ¥1.67 billion at the end of the previous year[24] - The company reported a net increase in cash and cash equivalents of approximately ¥329.44 million during the quarter[24] - Total assets at the end of the reporting period were approximately ¥5.53 billion, up 0.69% from the end of the previous year[11] - As of March 31, 2023, total assets amounted to ¥5.53 billion, showing a slight increase from ¥5.49 billion[36] - The company's total current assets decreased to ¥3,224,795,967.12 in Q1 2023 from ¥3,488,519,972.93 in Q1 2022, a decline of 7.6%[70] - Non-current assets increased to ¥2,301,977,619.64 in Q1 2023 from ¥2,000,475,868.79 in Q1 2022, reflecting a growth of 15.1%[70] Liabilities and Equity - The total liabilities decreased from ¥1.34 billion to ¥1.24 billion, indicating improved financial health[36] - The company’s equity attributable to shareholders increased by 3.40% year-on-year, reaching approximately ¥4.16 billion[11] - Total equity attributable to shareholders of the parent company was CNY 4,157,390,941.28, an increase from CNY 4,020,637,920.82[60] Research and Development - R&D investment totaled approximately ¥80.01 million, accounting for 11.65% of operating revenue, a decrease of 0.42 percentage points[11] - Research and development expenses for Q1 2023 amounted to ¥80,011,141.60, compared to ¥68,022,389.62 in Q1 2022, indicating a 17.5% increase[73] Operational Highlights - The company accelerated the layout of new product solutions, focusing on automation sample libraries, biocultures, and laboratory consumables, which are becoming new growth drivers[28] - In Q1 2023, the company's gross margin increased to 51.02%, reflecting improved operational capabilities[29] - The life sciences segment grew by 19.02%, while the medical innovation segment increased by 24.89%[51] - The Internet of Things solutions business experienced a year-on-year growth of 23.34%[51] - The company completed the acquisition of Thick Hong Intelligent Technology, enhancing its automation solution matrix for hospital users[28] - The company launched new AI automation vaccine workstations and digital public health examination solutions, expanding its offerings in public health[28] Awards and Recognition - The company was awarded the "China Industrial Grand Prize," the highest award in the industrial sector, and recognized as a national green factory[28] Other Financial Metrics - The company’s financial expenses increased by ¥400.30 million, primarily due to changes in exchange gains and losses during the reporting period[8] - The company received a VAT refund of approximately ¥5.82 million, classified as a regular profit and loss item, benefiting from national policy[30] - Cash flow from investment activities yielded a net amount of ¥243.63 million, a decrease from ¥879.11 million year-on-year[40] - Other comprehensive income after tax for Q1 2023 was ¥98,055.44, compared to a loss of ¥129,606.57 in Q1 2022[73] - Total operating costs for Q1 2023 were ¥557,268,271.77, up from ¥461,609,356.07 in Q1 2022, reflecting a 20.7% increase[72]

证券代码：688139 证券简称：海尔生物 公告编号：2023-020 青岛海尔生物医疗股份有限公司 关于参加 2022 年度医疗器械专场集体业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性 承担个别及连带责任。 重要内容提示： （网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 4 月 27 日(星期四)16:00 前登录上证路演中心网站首页 点击"提问预征集"栏目或通过公司邮箱 haierbiomedical@haierbiomedical.com 进行提问。公司将在文字互动环节对投 资者普遍关注的问题进行回答。 青岛海尔生物医疗股份有限公司（以下简称"公司"）已于 2023 年 3 月 29 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年 度经营成果、财务状况，公司参与了由上海证券交易所主办的 2022 年度医疗器 械专场集体业绩说明会，此次活动将采用视频和网络文字互动的方式举行，投 资者可登录上海证券交 ...

Financial Performance - In 2022, the company's operating income reached ¥2,864,044,617.29, representing a year-on-year increase of 34.72%[32]. - The net profit attributable to shareholders was ¥600,791,263.18, a decrease of 28.90% compared to the previous year[32]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥532,875,645.95, an increase of 27.47% year-on-year[32]. - The company's total assets at the end of 2022 amounted to ¥5,488,995,841.72, reflecting a 12.02% increase from the previous year[32]. - The basic earnings per share for 2022 was ¥1.89, down 29.21% from ¥2.67 in 2021[32]. - The company's net assets attributable to shareholders increased by 10.98% to ¥4,020,637,920.82 by the end of 2022[32]. - The company reported a net cash flow from operating activities of ¥632,429,327.27, an increase of 6.87% year-on-year[32]. Dividend and Share Capital - The company plans to distribute a cash dividend of 4.5 RMB per 10 shares, totaling approximately 142.42 million RMB (including tax) based on a total share capital of 317,952,508 shares as of December 31, 2022[7]. - The company has a total share capital of 317,952,508 shares, with 1,459,586 shares held in a repurchase account, affecting the dividend distribution calculation[7]. - The company has a total share count of 317,952,508 after the issuance of 880,750 new shares, with 58.15% being unrestricted circulating shares[149]. - The company plans to repurchase up to 1 million shares, which would account for approximately 0.32% of the total share capital, with a maximum repurchase price of 100 RMB per share[194]. - The lower limit of the repurchase plan estimates around 500,000 shares, representing about 0.16% of the total share capital[194]. Corporate Governance - The audit report issued by Ernst & Young Huaming confirms the financial statements' accuracy and completeness, providing assurance to stakeholders[6]. - The company has confirmed that all board members attended the board meeting, ensuring governance and oversight in decision-making processes[10]. - The company has not disclosed any special arrangements in corporate governance, indicating standard practices are in place[15]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties, ensuring financial integrity[15]. - The company has not violated decision-making procedures for external guarantees, indicating adherence to regulatory compliance[15]. - The company has not disclosed any related party transactions among the top ten shareholders, ensuring transparency in ownership[188]. - The company is committed to maintaining its corporate governance standards, as evidenced by the absence of undisclosed related party relationships among shareholders[188]. Strategic Development and Future Plans - The company has outlined its future plans and strategic development in the annual report, although these do not constitute binding commitments to investors[12]. - The company is actively expanding its market presence, particularly in the life sciences and healthcare sectors, driven by national strategies promoting technological innovation and healthcare services[74]. - The company has established a "dual carbon" task force to promote green and low-carbon development across various departments[38]. - The company has a commitment to not transfer or reduce its shareholdings for a period of three months starting from October 25, 2022[58]. - The company has committed to limiting the annual transfer of shares to no more than 25% of the total shares held during its tenure as a director or senior management[58]. Research and Development - The company invested 10.21% of its operating income in R&D, a decrease of 0.91 percentage points from the previous year[32]. - The company introduced over 30 new products in microbiological culture media and protein expression technology, expanding its market in biopharmaceutical research and industrial production[90]. - The company increased its patent portfolio by 50%, with a total of 271 new patents filed in 2022, including 11 invention patents[90]. - The company has made significant advancements in automation technology, including a self-innovated -80℃ automated biological sample storage technology[87]. - The company is focused on enhancing its technological capabilities to meet the growing demand for comprehensive solutions in biological experiments, drug development, and medical services[74]. Market Expansion - The company's overseas market revenue reached 83,389.89 million yuan, representing a year-on-year growth of 56.45%[82]. - The domestic market generated revenue of CNY 2,021.53 million, reflecting a year-on-year growth of 27.50%[175]. - The company expanded its overseas distribution network to over 700, covering 8 new countries in Central and Eastern Europe[176]. - The company has established long-term partnerships with over 40 international organizations, including WHO and UNICEF[153]. - The company has successfully broken foreign monopolies in biomedical low-temperature technology and has received the only National Science and Technology Progress Award in the industry[152]. Operational Efficiency - The company has optimized its entire value chain through digitalization, enhancing operational efficiency across various departments[151]. - The company maintains a complete control process from customer demand collection to after-sales service, ensuring operational consistency[158]. - The company has implemented a production management system to ensure product quality meets regulatory requirements, including monitoring and measurement controls[67]. - The company has a structured approach to supplier qualification and procurement, ensuring that suppliers are vetted before entering the supplier database[65]. Financial Management - The total amount of funds raised through public stock issuance was approximately ¥1.23 billion, with a net amount of ¥1.16 billion after deducting issuance costs[113]. - The cumulative investment amount in fundraising projects reached approximately ¥605.94 million, representing a progress rate of 60.59%[113]. - The company plans to use up to ¥650 million of temporarily idle fundraising for cash management, investing in safe and liquid products[118]. - The company has invested approximately ¥10.82 billion in principal-protected financial products, with an outstanding balance of ¥1.49 billion[125]. - The company has issued structured deposits totaling ¥6 billion, with interest rates ranging from 1.3% to 3.29%[108].

1 证券代码：688139 证券简称：海尔生物 青岛海尔生物医疗股份有限公司 投资者关系活动记录表 编号：2022-005 | --- | --- | --- | --- | |----------------|-------------------------------------|---------|---------------------------------------------------------------------------------------------------------| | | | | | | 投资者关系活动 | 特定对象调研 | □ | 分析师会议 | | 类别 | □媒体采访 | □ | 业绩说明会 | | | □新闻发布会 | □ | 路演活动 | | | □现场参观 | □ | 电话会议 | | | □其他 （请文字说明其他活动内容） | | | | 参与单位名称 | 共 267 | | 家机构，参会机构名单详见附表。 | | 时间 | 2022 年 4 月 29 日— 5 | 月 13 | 日 | | 参会方式 | 电话会议 | | | | 上市公司接待 ...

1 证券代码：688139 证券简称：海尔生物 青岛海尔生物医疗股份有限公司 投资者关系活动记录表 编号：2022-006 | --- | --- | --- | --- | |-----------------------|---------------------------------------|---------|-----------------------------------------------------------| | | | | | | 投资者关系活动 | 特定对象调研 | □ | 分析师会议 | | 类别 | □媒体采访 | □ | 业绩说明会 | | | □新闻发布会 | □ | 路演活动 | | | □现场参观 | □ | 电话会议 | | | □其他 （请文字说明其他活动内容） | | | | 参与单位名称 | 共 157 构，参会机构名单详见附表。 | | | | 时间 | 2022 年 5 月 17 日— 6 | 月 17 | 日 | | 参会方式 | 电话会议、现场会议 | | | | 上市公司接待人 员姓名 | 董事会秘书黄艳莉、证券事务代表蒋宏建 | | | | ...

Financial Performance - The company's operating revenue for Q3 2022 reached ¥807,395,894.65, representing a year-on-year increase of 36.34%[7] - The net profit attributable to shareholders for Q3 2022 was ¥160,875,376.68, with a year-on-year increase of 28.59%[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥136,145,703.57, reflecting a year-on-year increase of 36.00%[7] - The company's operating revenue increased by 36.52% during the reporting period, driven by growth in both IoT solutions and traditional business segments[22] - Total operating revenue for the first three quarters of 2022 reached CNY 2,075,274,671.51, a 36.4% increase from CNY 1,520,143,956.41 in the same period of 2021[44] - Net profit for the third quarter of 2022 was CNY 464,543,504.50, down 33.7% from CNY 700,445,995.03 in the previous year[47] - The total comprehensive income attributable to the parent company was 463,660,821.15 CNY, a decrease from 722,641,850.20 CNY in the previous year, representing a decline of approximately 35.8%[49] - Basic and diluted earnings per share were both 1.46 CNY, down from 2.20 CNY in the same period last year, indicating a decrease of about 33.6%[49] Research and Development - Research and development expenses totaled ¥77,377,397.24 in Q3 2022, accounting for 9.58% of operating revenue, a decrease of 4.17 percentage points year-on-year[11] - Research and development expenses for the first three quarters amounted to CNY 211,246,026.69, an increase from CNY 174,004,095.97, representing a growth of 21.4%[44] Market Growth - The domestic market grew by 30.53% year-on-year, while the overseas market saw a growth of 54.02%[15] - The life sciences digital scenario revenue increased by 46.31% year-on-year, while the medical innovation digital scenario revenue grew by 29.52%[13] Assets and Liabilities - The total assets of the company at the end of Q3 2022 were ¥5,142,698,967.95, an increase of 4.96% compared to the end of the previous year[11] - As of September 30, 2022, the total assets of the company reached approximately RMB 5.14 billion, an increase from RMB 4.90 billion at the end of 2021, reflecting a growth of about 4.95%[36] - The company's current assets totaled approximately RMB 3.49 billion, compared to RMB 3.46 billion at the end of 2021, indicating a slight increase of around 0.70%[39] - The company's non-current assets totaled approximately RMB 1.66 billion, up from RMB 1.44 billion at the end of 2021, showing an increase of about 14.83%[39] - The total liabilities decreased to CNY 1,210,378,778.46 from CNY 1,261,079,904.20, reflecting a reduction of approximately 4.0%[44] - The company's total equity increased to CNY 3,932,320,189.49 from CNY 3,638,749,093.87, reflecting an increase of approximately 8.1%[44] Cash Flow - The cash flow from operating activities decreased by 56.30%, primarily due to an increase in cash payments for goods and services[27] - Cash inflow from operating activities totaled 1,958,373,149.95 CNY, compared to 1,894,103,983.24 CNY in the previous year, reflecting an increase of approximately 3.4%[53] - Net cash flow from operating activities was 193,535,402.24 CNY, a significant decrease of 56.3% from 442,839,649.28 CNY in the prior year[53] - Cash inflow from investment activities was 9,754,732,369.18 CNY, up from 5,001,698,658.93 CNY, marking an increase of approximately 94.5%[54] - The net cash flow from financing activities was -208,117,313.00 CNY, compared to -147,113,388.82 CNY in the previous year, indicating a decline of about 41.5%[54] Other Financial Metrics - The weighted average return on equity was 4.21%, an increase of 0.44 percentage points year-on-year[11] - The total comprehensive income decreased by 35.61%, mainly due to changes in net profit during the reporting period[26] - The company reported a significant decrease of 60.24% in notes receivable, mainly due to the maturity and acceptance of notes during the reporting period[22] - The company experienced a 44.44% decrease in taxes payable, mainly due to a reduction in income tax payable during the reporting period[22] - The company reported a foreign exchange impact on cash and cash equivalents of 32,144,292.63 CNY, compared to 8,681,857.50 CNY in the previous year, showing an increase of approximately 270.5%[54]

Financial Performance - Haier Biomedical reported a revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[19]. - The company achieved a net profit of RMB 300 million, up 20% compared to the same period last year[19]. - The company's operating revenue for the first half of the year reached ¥1,267,878,776.86, representing a year-on-year increase of 36.63% compared to ¥927,954,150.02 in the same period last year[26]. - The net profit attributable to shareholders of the listed company was ¥300,570,997.11, a decrease of 47.55% from ¥573,077,466.11 in the previous year[26]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 26.57% to ¥272,123,675.07 from ¥214,999,373.27 in the same period last year[29]. - Basic earnings per share decreased by 47.51% to ¥0.95 from ¥1.81 in the previous year[30]. - The weighted average return on net assets decreased by 10.81 percentage points to 8.12% from 18.93% in the previous year[30]. - The net cash flow from operating activities was ¥184,335,005.22, a decrease of 15.00% from ¥216,874,817.07 in the previous year[29]. - The company's net assets attributable to shareholders increased by 3.32% to ¥3,742,947,461.44 from ¥3,622,799,326.47 at the end of the previous year[29]. - The company confirmed stock incentive expenses during the reporting period, impacting net profit figures[31]. Market Expansion and Strategy - User data indicated a growth in active users by 25%, reaching a total of 500,000 users[19]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2025[19]. - Haier Biomedical is exploring potential acquisitions to enhance its product portfolio and market reach[19]. - The company has established a presence in over 130 countries and regions, serving thousands of end-users in the healthcare sector, including major hospitals and research institutions in China[43]. - The company has established nearly 200 domestic distribution networks and over 600 overseas distribution networks, serving over 500 after-sales service partners[125]. - The company's overseas business has seen rapid growth in Southeast Asia and South America, contributing to the local healthcare system upgrades[134]. Research and Development - Haier Biomedical is investing RMB 200 million in R&D for new product development, focusing on advanced biomedicine technologies[19]. - Research and development expenses accounted for 10.56% of operating revenue, an increase of 0.58 percentage points compared to 9.98% in the previous year[30]. - The total R&D investment reached approximately ¥133.87 million, a 44.61% increase compared to ¥92.57 million in the same period last year, with R&D expenses accounting for 10.56% of operating revenue[98]. - The company has applied for 178 new patents and obtained 126 authorizations in the first half of 2022, indicating a rapid increase in intellectual property achievements[89]. - The company has established an open R&D model, attracting top talent and collaborating with universities and research institutions to enhance its innovation capabilities[93]. - The company has led or participated in the drafting of several national standards, reinforcing its position as an industry leader in standard-setting[94]. Product Development and Innovation - The company has launched a new solar-powered vaccine storage solution, aiming to capture a significant share of the cold chain logistics market[19]. - The company has developed core technologies in automation, microbial culture, and rapid cooling centrifugation, enhancing its product offerings in laboratory solutions[42]. - The company has achieved significant technological breakthroughs in low-temperature storage, establishing a complete technical system that breaks foreign monopolies, and has received 22 provincial and national science and technology awards[68]. - The company has developed a low-temperature refrigeration system that maintains an internal temperature fluctuation of 0 degrees, ensuring long-term reliability without the use of lubricating oil[79]. - The company has introduced a mobile vaccination system that integrates IoT and cloud computing for comprehensive vaccine traceability and management[85]. - The company has developed a digital nucleic acid sampling system that enhances sampling efficiency and allows for contactless registration, reducing sampling time to just 10 seconds[92]. - The company has completed the development of a new generation of intelligent safety cabinets, focusing on the European and American market needs, and has obtained CE and NSF certifications[104]. Sustainability and Environmental Commitment - Haier Biomedical is committed to sustainability, with plans to reduce carbon emissions by 15% by 2025[19]. - The company has implemented measures to reduce carbon emissions through optimized production processes and resource allocation[171]. - The company has adopted environmentally friendly materials and technologies, including LBA foaming technology, to enhance sustainability[171]. - The company has received multiple energy-saving and environmental certifications for its products, including CQC and EPA certifications[171]. Financial Commitments and Governance - The company has committed to not transferring or entrusting the management of its pre-IPO shares for 36 months from the date of listing on the Shanghai Stock Exchange[176]. - The company and its major shareholders have made commitments regarding stock repurchase and measures to stabilize stock prices for three years post-listing[181]. - The company has outlined specific measures to address any potential dilution of returns for investors[181]. - The company has confirmed that all commitments related to the IPO have been fulfilled in a timely manner[176]. Operational Challenges and Risk Management - The management highlighted the importance of risk management strategies in navigating potential market challenges[19]. - The company is exposed to foreign exchange risks due to its export business, primarily settled in USD, and has strategies in place to mitigate these risks[149]. - The company aims to enhance its supply chain by optimizing transportation routes and expanding its supplier network to mitigate raw material supply risks[146].

Revenue and Profitability - The company's revenue for Q1 2022 was CNY 563,453,088.49, representing a year-on-year increase of 36.22%[6] - Net profit attributable to shareholders decreased by 72.96% to CNY 113,524,222.50, while the net profit after deducting non-recurring gains and losses increased by 7.53% to CNY 101,234,822.19[6] - The company's operating revenue increased by 36.22% due to high growth in both IoT solutions and traditional businesses[22] - The total profit decreased by 73.95%, influenced by the growth in operating scale and one-time gains from the disposal of joint ventures[22] - Basic earnings per share for Q1 2022 were ¥0.36, down from ¥1.32 in Q1 2021[45] Research and Development - The company's R&D investment totaled CNY 68,022,389.62, up 64.55% year-on-year, accounting for 12.07% of revenue, an increase of 2.08 percentage points[6] - Research and development expenses surged by 64.55%, reflecting ongoing investment in R&D projects[22] - R&D expenses in Q1 2022 amounted to ¥68,022,389.62, an increase of 64.5% from ¥41,339,082.29 in Q1 2021[43] Cash Flow and Liquidity - The company achieved a net cash flow from operating activities of CNY 97,673,285.67, a decrease of 21.34% year-on-year[9] - Cash and cash equivalents rose by 118.98%, primarily due to increased net cash inflow from investment activities[22] - Operating cash inflows totaled $590,285,019.47, a decrease of 15.6% from $699,312,434.03[49] - The net increase in cash and cash equivalents was $922,441,143.20, contrasting with a decrease of $790,412,666.82 in the prior period[51] - The ending balance of cash and cash equivalents stood at $1,669,686,010.00, up from $1,004,000,369.06[51] Market Expansion and Business Growth - The IoT solution business saw an impressive revenue growth of 88.42%, contributing to 35.33% of total revenue[12] - Revenue from the life sciences digital scenario grew by 46.78%, while revenue from medical innovation digital scenarios increased by 27.39%[12] - The company has expanded its market presence, adding 49 new channels in regions such as Africa, South America, and Southeast Asia, while enhancing local personnel in Europe and North America[16] - The newly launched biochemical incubator supports the expansion into genetic disease screening and microbial diagnostics, broadening the user base from biopharmaceutical companies to medical institutions[14] Financial Position - As of March 31, 2022, the company's total assets amounted to approximately CNY 4.96 billion, an increase from CNY 4.90 billion at the end of 2021, reflecting a growth of about 1.1%[34] - The company's cash and cash equivalents reached CNY 1.70 billion, significantly up from CNY 774.39 million in the previous year, indicating an increase of approximately 118%[34] - The company's accounts receivable increased to CNY 137.35 million from CNY 112.29 million, representing a growth of about 22.3% year-over-year[34] - The total current liabilities decreased slightly to CNY 1.12 billion from CNY 1.14 billion, showing a reduction of approximately 3.3%[37] - The company's long-term equity investments rose to CNY 115.26 million, up from CNY 113.19 million, marking an increase of about 1.8%[36] Employee Compensation and Expenses - The company reported a decrease in employee compensation liabilities to CNY 46.79 million from CNY 66.59 million, a reduction of about 29.8%[37] - Payments to employees increased to $125,522,642.75 from $96,499,063.35, reflecting a rise of 30.2%[49] - Financial expenses decreased by 68.06%, mainly due to changes in exchange gains and losses[22] Other Financial Metrics - The weighted average return on net assets was 3.09%, a decrease of 10.98 percentage points compared to the previous year[9] - The company reported a significant increase in interest income by 195.22%, attributed to the rise in cash and cash equivalents[22] - The company received a VAT refund of 8,033,581.45 RMB, classified as a recurring profit item due to its relevance to normal business operations[22] - The company reported a significant drop in investment income, with a loss of ¥22,024,811.41 in Q1 2022 compared to a gain of ¥377,446,127.41 in Q1 2021[43]

Financial Performance - The company's operating revenue for 2021 was CNY 2,125,862,739.15, representing a year-on-year increase of 51.63%[30]. - The net profit attributable to shareholders for 2021 was CNY 845,035,305.76, a significant increase of 121.82% compared to the previous year[30]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 32.97% to CNY 418,046,340.77 in 2021[30]. - Basic earnings per share for 2021 rose to CNY 2.67, reflecting a year-on-year growth of 122.50%[33]. - The total profit reached 960.87 million RMB, with a year-on-year increase of 126.49%[47]. - The company's cash flow from operating activities decreased by 15.05% to CNY 591,798,010.34 due to increased cash payments for inventory and services[34]. - The gross profit margin decreased to 50.08%, down by 0.51 percentage points due to rising costs of raw materials[163]. Dividend Distribution - The company plans to distribute a cash dividend of 5.0 RMB per 10 shares, totaling approximately 158.2 million RMB, which represents 18.72% of the net profit attributable to shareholders for 2021[7]. - As of December 31, 2021, the total share capital of the company was 317,071,758 shares, with 316,391,758 shares eligible for the dividend after excluding repurchased shares[7]. Research and Development - Research and development expenses accounted for 11.12% of operating revenue in 2021, up from 10.75% in 2020[33]. - R&D expenses amounted to ¥236,307,039.02, representing a 56.79% increase compared to the previous year's ¥150,719,187.87[116]. - The company applied for 269 new patents and obtained 197 authorizations in 2021, totaling 539 patents by the end of December 2021[109]. - The company has established a comprehensive open innovation system, enhancing its competitive edge in the biomedical low-temperature storage and biosafety solution sectors[142]. Market Expansion and User Engagement - The company plans to continue expanding its global market presence and enhancing its product innovation through increased R&D investment[34]. - The company is actively pursuing global market expansion, with multiple products certified by international standards such as NSF/ANSI and DIN[51]. - The company expanded its user base significantly, doubling the number of users in niche areas such as CXO, cell therapy, and gene therapy[49]. - The company is deepening its global market presence by establishing localized teams and systems to better understand and meet user needs, thereby increasing global market share[199]. Operational Risks and Governance - The company has outlined various operational risks and corresponding mitigation measures in the management discussion and analysis section of the report[5]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[10]. - The company has not experienced any violations of decision-making procedures regarding external guarantees[10]. - The company has not disclosed any special arrangements for corporate governance[10]. Technological Advancements - The company has made significant technological advancements, including breakthroughs in automation, microbial culture, environmental simulation, and rapid cooling centrifugation technologies[66]. - The company has developed a comprehensive low-temperature storage solution for biomedical applications, covering sample safety, drug safety, vaccine safety, and blood safety, and has achieved a breakthrough in low-temperature technology, breaking foreign monopolies[66]. - The company launched innovative IoT solutions for blood safety management and vaccine storage, enhancing user experience and supporting the upgrade of the medical industry[93]. Employee and Talent Development - The workforce increased to over 2,000 employees, with 78% of new hires in R&D and marketing roles, strengthening the talent pool[62]. - The company has implemented a diverse employee incentive mechanism, including a restricted stock incentive plan launched in 2021, aimed at attracting and retaining talent[65]. - The company has established a talent reserve pool and a tiered training system to continuously stimulate employee potential and maintain innovation vitality[65]. Compliance and Standards - The company has led or participated in drafting 19 national, industry, and group standards, promoting the standardized development of the industry[66]. - The company participated in the formulation of six national standards, including those for automated low-temperature biological sample banks and vaccine cold chain logistics, establishing industry leadership[114]. Investment and Financial Management - The company’s investment activities resulted in a net cash outflow of CNY 1,501,417,001.14, a significant increase of 1,010.33% compared to the previous year[160]. - The company is actively managing foreign exchange risks through hedging strategies and locking in exchange rates[152]. - The company recognized a gain from the disposal of 17.11% equity in the associate company Mesa during the reporting period[177].

Financial Performance - The company's revenue for Q3 2021 reached ¥592.19 million, representing a year-on-year increase of 53.09%[6] - Net profit attributable to shareholders for Q3 2021 was ¥125.11 million, a 6.41% increase compared to the same period last year[6] - The total revenue for the first three quarters of 2021 was ¥1.52 billion, reflecting a growth of 54.89% year-on-year[6] - Revenue increased by 54.89% driven by high growth in IoT solutions and traditional business[24] - Net profit rose by 155.20% attributed to business scale growth and investment income from disposed joint ventures[24] - The company reported a profit margin increase of 157.99% due to operational scale growth[24] - Total operating revenue for the first three quarters of 2021 reached ¥1,520,143,956.41, a significant increase from ¥981,453,217.89 in the same period of 2020, representing a growth of approximately 54.9%[47] - Net profit for the third quarter of 2021 was ¥700,445,995.03, up from ¥274,465,658.03 in the same quarter of 2020, reflecting a growth of approximately 155.0%[50] - Basic earnings per share for the third quarter of 2021 were ¥2.20, compared to ¥0.86 in the same quarter of 2020, marking an increase of about 156.0%[52] - The company reported a total comprehensive income of ¥724,903,178.40 for the third quarter of 2021, compared to ¥271,656,099.54 in the same quarter of 2020, representing an increase of approximately 167.0%[52] Research and Development - Research and development expenses amounted to ¥81.43 million in Q3 2021, a significant increase of 66.92% year-on-year, accounting for 13.75% of total revenue[9] - Research and development expenses increased by 61.97% due to investments in IoT R&D projects[24] - Research and development expenses for the first three quarters of 2021 were ¥174,004,095.97, up from ¥107,428,279.39 in 2020, reflecting an increase of approximately 62.0%[47] - The company launched new products including a program cooling instrument and a new series of centrifuges, obtaining over 20 related patents[12] Market Performance - The domestic market generated revenue of ¥1.12 billion in the first three quarters, a 66.56% increase year-on-year, driven by IoT solutions[12] - The overseas market revenue reached ¥390.97 million in the first three quarters, showing a growth of 32.79%, with Q3 growth accelerating to 79.15%[12] Cash Flow and Assets - The net cash flow from operating activities for the first three quarters was ¥442.84 million, reflecting an 8.03% increase year-on-year[6] - Cash flow from operating activities for the first three quarters of 2021 was ¥1,829,289,551.15, compared to ¥1,155,364,523.62 in 2020, indicating a growth of about 58.3%[52] - The total assets as of the end of Q3 2021 were ¥4.69 billion, a 19.08% increase compared to the end of the previous year[9] - The company's current assets totaled RMB 3,486,328,814.89, compared to RMB 2,733,965,717.27 in the previous year, indicating a growth of approximately 27.6%[37] - The company's inventory increased significantly to RMB 392,481,243.48, up from RMB 247,949,856.20, representing a growth of approximately 58.2%[37] - The total cash and cash equivalents at the end of the period stood at CNY 799,023,807.51, down from CNY 961,085,040.10 at the end of the previous year[57] Liabilities and Equity - The total liabilities amounted to RMB 2,486,328,814.89, showing an increase from the previous year's liabilities[41] - The total liabilities increased to ¥1,292,765,727.02 in 2021 from ¥1,158,084,744.73 in 2020, representing a growth of approximately 11.5%[43] - Total equity attributable to shareholders reached ¥3,391,034,403.28 in 2021, compared to ¥2,775,877,783.68 in 2020, indicating an increase of about 22.1%[43] - The company reported a significant increase in contract liabilities to RMB 393,869,028.82 from RMB 247,818,290.15, reflecting a growth of about 59%[41] Investment Activities - Cash outflow from investment activities was CNY 6,301,496,005.26, up from CNY 4,213,890,184.72 year-over-year[55] - The net cash flow from investment activities was negative at CNY -1,299,797,346.33, worsening from CNY -768,700,793.76 in the previous year[55] - The company received CNY 4,508,442,851.66 from the recovery of investments, an increase from CNY 3,400,020,000.00 in the previous year[55] - Cash paid for purchasing fixed assets and intangible assets was CNY 140,266,005.26, compared to CNY 55,598,894.72 in the same period last year[55] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,026[27] - The largest shareholder, Qingdao Haier Biomedical Holdings Co., Ltd., holds 31.73% of the shares[27]